Larisa J. Geskin

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

Richard Piekarz, Robin Frye, Maria L. Turner et al. · Journal of Clinical Oncology · 2009 · 737 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer

Elise A. Olsen, Sean Whittaker, Youn H. Kim et al. · Journal of Clinical Oncology · 2011 · 658 citations · Full text

Medicine, Dermatology, Oncology +17

Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium

Pietro Quaglino, Milena Maule, H. Miles Prince et al. · Annals of Oncology · 2017 · 136 citations · Full text

Medicine, Dermatology, Oncology +12

Romidepsin in peripheral and cutaneous T‐cell lymphoma: mechanistic implications from clinical and correlative data

Susan E. Bates, Robin A. Eisch, Alexander Ling et al. · British Journal of Haematology · 2015 · 66 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).

Richard Piekarz, Robin Frye, Steven L. Allen et al. · Blood · 2008 · 40 citations

Medicine, Oncology, Pharmacotherapy +7